ProMIS Neurosciences Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Neil K. Warma

Chief executive officer

US$40.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.1yrs
CEO ownership	n/a
Management average tenure	3.7yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO

Neil K. Warma (61 yo)

1.1yrs

Tenure

US$40,000

Compensation

Mr. Neil K. Warma, MBA, serves as Chief Executive Officer and President of ProMIS Neurosciences, Inc. from August 1, 2024 and has been its Director since December 30, 2023 and was its Interim Chief Executi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Eugene Williams	Co-Founder & Chairman	9.6yrs	US$275.00k	0.49% $ 166.3k
Neil K. Warma	CEO, President & Director	1.1yrs	US$40.00k	no data
Neil Cashman	Co-Founder	20.7yrs	US$378.82k	0.35% $ 119.5k
Gavin Malenfant	Chief Operating Officer	3.3yrs	US$435.90k	0.0081% $ 2.8k
Daniel Geffken	Chief Financial Officer	7.8yrs	US$142.40k	0.018% $ 6.1k
Johanne Kaplan	Chief Development Officer	8.5yrs	US$525.57k	0.015% $ 5.0k
David Wishart	Chief Physics Officer	3.7yrs	no data	no data
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	no data	no data
Larry Altstiel	Chief Medical Officer	2.8yrs	no data	no data

3.7yrs

Average Tenure

65yo

Average Age

Experienced Management: PMN's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Eugene Williams	Co-Founder & Chairman	9.6yrs	US$275.00k	0.49% $ 166.3k
Neil K. Warma	CEO, President & Director	3.7yrs	US$40.00k	no data
Neil Cashman	Co-Founder	18yrs	US$378.82k	0.35% $ 119.5k
William Wyman	Independent Director	10.8yrs	US$40.00k	0.19% $ 65.5k
William Mobley	Member of Scientific Advisory Board	7.6yrs	no data	no data
Patrick Kirwin	Independent Director	9.6yrs	US$40.00k	0.30% $ 103.1k
Joshua Mandel-Brehm	Independent Director	3.3yrs	US$40.00k	0% $ 0
Sharon Cohen	Member of Scientific Advisory Board	6.8yrs	no data	no data
Andre Strydom	Member of Scientific Advisory Board	5.4yrs	no data	no data
Michelle Hastings	Member of Scientific Advisory Board	no data	no data	no data
Madge Shafmaster	Lead Independent Director	3.3yrs	US$40.00k	0.64% $ 216.7k
Carsten Korth	Member of Scientific Advisory Board	3yrs	no data	no data

6.8yrs

Average Tenure

65yo

Average Age

Experienced Board: PMN's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 09:55
End of Day Share Price	2025/01/03 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ProMIS Neurosciences, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Thomas Shrader	BTIG
Eddie Hickman	Guggenheim Securities, LLC
Douglas Loe	Leede Jones Gable Inc

ProMIS Neurosciences Management

Management criteria checks 4/4

Key information

Recent management updates

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources